Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (BCRX) has granted inducement options to nine new employees for a total of 178,500 shares of its common stock as of September 30, 2021. The options have an exercise price of $14.37 per share, matching the stock's closing price on that date. Vesting occurs in four equal installments annually, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and supports BioCryst's commitment to attracting talent in the rare disease treatment sector.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 2021 Cantor Virtual Healthcare Conference on September 28, 2021, at 2:00 p.m. ET. Investors can access the live audio webcast and replay on the company's website. BioCryst specializes in developing novel oral medicines for rare diseases, with approved products such as ORLADEYO® for certain medical conditions. The company is also working on several other treatments, including BCX9930 for complement-mediated diseases and galidesivir for viral infections.
BioCryst Pharmaceuticals (Nasdaq:BCRX) has appointed Dr. Amy McKee to its board of directors, enhancing its regulatory expertise. Dr. McKee, a former deputy center director at the FDA's Oncology Center of Excellence, brings over a decade of experience in drug development and regulatory strategy. She will aid in advancing the company's pivotal trials for BCX9930, aimed at treating PNH and other complement-mediated diseases. This strategic move is expected to strengthen BioCryst's leadership as it continues to develop innovative treatments for rare diseases.
On September 15, 2021, BioCryst Pharmaceuticals (BCRX) announced that the UK's NICE recommended ORLADEYO® (berotralstat) for preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older with at least two attacks per month. This marks the first oral, once-daily therapy for routine prevention of HAE attacks in these regions. The recommendation follows a successful Phase 3 trial, which showed an 80% average reduction in attack rates over time. ORLADEYO is already approved in the US and other regions, with further assessments expected in Scotland.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that the UAE's Ministry of Health has granted marketing authorization for ORLADEYO (berotralstat), designed to prevent recurrent attacks in patients aged 12 and older suffering from hereditary angioedema. This approval marks a significant advancement in treatment options for these patients. BioCryst has partnered with NewBridge Pharmaceuticals for distribution across the Gulf Cooperation Council (GCC) and Iraq, aiming to enhance market access for this innovative therapy.
BioCryst Pharmaceuticals (BCRX) will present at the 2021 Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 p.m. ET. Additionally, they will showcase their presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand starting September 13, 2021, at 7:00 a.m. ET. Investors can access the live audio webcast and replays on BioCryst's website. The company focuses on developing oral medicines for rare diseases and has several products approved or in development, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options to 18 new employees. The options allow the purchase of 199,000 shares at an exercise price of $15.92 and $16.15, corresponding to the closing stock prices on August 31 and September 1, 2021, respectively.
The options will vest in four equal annual installments, starting one year after the grant date, and are part of the Inducement Equity Incentive Plan, valid for 10 years.
BioCryst Pharmaceuticals (BCRX) announced the U.S. Department of Health and Human Services (HHS) has ordered an additional 10,000 doses of its antiviral influenza therapy, RAPIVAB, for approximately $7 million. This purchase will bolster the Strategic National Stockpile as part of a $34.7 million contract from 2018 to supply up to 50,000 doses over five years. With this order, BioCryst will have delivered 40,000 doses, enhancing preparedness for the upcoming influenza season. RAPIVAB is approved for treating acute uncomplicated influenza in patients over six months old.
BioCryst Pharmaceuticals has appointed Steven Galson, M.D. to its board of directors. Galson, a former director of the FDA Center for Drug Evaluation and Research, brings extensive experience from his time at Amgen and various health agencies. His track record includes overseeing significant drug developments, which the company hopes will aid in commercializing its ORLADEYO® treatment and advancing pipeline candidates like BCX9930. This leadership change comes at a crucial time as BioCryst focuses on expanding treatment options for rare diseases.
BioCryst Pharmaceuticals (BCRX) has announced that Health Canada and Swissmedic have accepted the submission for ORLADEYO (berotralstat) for reviewing its potential to prevent recurrent attacks in patients with hereditary angioedema (HAE) aged 12 and older. This marks a significant milestone in the company's efforts to provide a targeted oral therapy for HAE patients, as no such therapies currently exist in these regions. CEO Jon Stonehouse emphasizes that approval could introduce an essential treatment option for patients and physicians in Canada and Switzerland.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
